Antibacterial activity screening of a collection of Xenorhabdus strains led to the discovery of the 22 Odilorhabdins, a novel antibiotic class with broad-spectrum activity against Gram-positive and 23 Gram-negative pathogens. Odilorhabdins inhibit bacterial translation by a novel mechanism of 24 action on ribosomes. A lead-optimization program identified NOSO-502 as a promising 25 candidate. NOSO-502 has MIC values ranging from 0.5 to 4 µg/ml against standard 26 Enterobacteriaceae strains and carbapenem-resistant Enterobacteriaceae (CRE) isolates that 27 produce KPC, AmpC, or OXA enzymes and metallo-β-lactamases. In addition, this compound 28 overcomes multiple chromosome-encoded or plasmid-mediated resistance mechanisms of 29 acquired resistance to colistin. It is effective in mouse systemic infection models against E. coli 30 EN122 (ESBL) or E. coli ATCC BAA-2469 (NDM-1), achieving an ED50 of 3.5 mg/kg and 1-, 2-and 31 3-log reductions in blood burden at 2.6, 3.8, and 5.9 mg/kg, respectively, in the first model and 32 100% survival in the second, starting with a dose as low as 4 mg/kg. In a UTI model of E. coli 33 UTI89, urine, bladder and kidney burdens were reduced by 2.39, 1.96, and 1.36 log10 CFU/ml, 34 respectively, after injecting 24 mg/kg. There was no cytotoxicity against HepG2, HK-2, or HRPT 35 cells, no inhibition of hERG-CHO or Nav 1.5 -HEK current, and no increase of micronuclei at 512 36 µM. NOSO-502, a compound with a novel mechanism of action, is active against 37 Enterobacteriaceae, including all classes of CRE, has a low potential for resistance development, 38 shows efficacy in several mouse models, and has a favorable in vitro safety profile. 39 40 41 42 43 48 threat level: carbapenem-resistant Enterobacteriaceae (CRE) and Clostridium difficile (1). 49 Carbapenems are broad-spectrum -lactam antibiotics saved for the treatment of the most 50 serious infections. CRE have become resistant to all or nearly all antibiotics available and cause 51 many types of serious infection, such as those of the respiratory tract, urinary tract, abdomen 52 and bacteremia (2). The CDC estimates that 9,300 healthcare-associated infections are caused 53 each year in the United States by the two most common types of CRE, carbapenem-resistant 54
INTRODUCTION
Antibiotic-resistant infections are spreading around the world. The urgent need to discover new 45 families of antibacterial agents to counter the threat of drug-resistant infection is widely 46 recognized. The U.S. Centers for Disease Control and Prevention (CDC) recently published a report outlining the top 18 drug-resistant threats. Two were classified as "urgent" in terms of NOSO-502 is resistant to biotransformation by hepatocytes and microsomes. 135 NOSO-502 was resistant to biotransformation when incubated in mouse, rat, dog, monkey, and 136 human liver microsomes and hepatocytes during the in vitro study conducted to evaluate 137 metabolic stability. After 45 minutes, 70.5 to 78.6% of NOSO-502 remained after incubation with 138 microsomes of the different species. The half-lives of NOSO-502 in liver microsomes were 116, 139 129, 101, 147, and 145 min for mouse, rat, dog, monkey, and human, respectively. After 60 140 minutes, 79.5 to 91.9% of NOSO-502 remained after incubation with hepatocytes of the different 141 species. The half-lives of 194, 483, 698 , and 329 min for 142 mouse, rat, dog, monkey, and human microsomes respectively. 143 NOSO-502 shows variable stability in plasma of different species. 144 NOSO-502 showed variable stability to biotransformation when incubated in mouse, rat, dog, 145 monkey, and human plasma; 10.1 to 61.2% of NOSO-502 remained after incubation with plasma 146 of the different species over the 120-min test period. The half-lives of 36, 147 158, 96, and 79 min for mouse, rat, dog, monkey, and human plasma, respectively. 148 Pharmacokinetics. 149 The pharmacokinetics of NOSO-502 was evaluated in normal female CD-1 mice or normal female 150 Sprague-Dawley rats. NOSO-502 was administered intravenously at 30 mg/kg to mice and 15 151 mg/kg to rats. The concentration-versus-time curves and the results of the pharmacokinetic 152 analysis are summarized in Figure 3 . In mice, NOSO-502 displayed moderate clearance (1.13 153 L/h/kg), a moderate volume of distribution (0.66 L/kg), and a half-life of 25 min. The 154 pharmacokinetics of NOSO-502 in rats showed a longer half-life (90 min) but were consistent 155 with the results in mice, with a plasma clearance of 1.92 L/h/kg and a volume of distribution of 156 0.94 L/kg. NOSO-502 showed moderate plasma protein binding, with 19.8, 20.5, 17.6, and 18 .7% NOSO-502 shows efficacy in several murine infection models. 159 The efficacy of NOSO-502 was evaluated in murine infection models to determine whether 160 NOSO-502 has potential as a clinical therapy. In vivo efficacy studies were conducted by 161 administering NOSO-502 subcutaneously. The efficacy of NOSO-502 was first assessed in a 162 neutropenic murine sepsis infection model. This model, with E. coli EN122 (ESBL, clinical isolate), 163 was established in female NMRI mice. NOSO-502 was administered subcutaneously 1 h post- 164 inoculation at set concentrations of 1.3, 2.5, 5, 10, 20, and 40 mg/kg, whereas colistin was 165 administered by the same route at 5 mg/kg. Five hours post-challenge, blood samples were 166 collected, and the mice euthanized. Blood was serially plated and colonies enumerated to 167 determine the CFU/ml of blood. NOSO-502 was highly effective, achieving an ED50 of 3.5 mg/kg 168 and 1-, 2-and 3-log reductions in blood burden at 2.6, 3.8, and 5.9 mg/kg, respectively (Fig. 4) . 169 A mouse E. coli UTI89 upper urinary tract infection model was established in female C3H/HeN 170 mice. Administration of 24 mg/kg NOSO-502 once daily resulted in a statistically significant 171 reduction in urine, bladder, and kidney burdens relative to vehicle control animals. At four days 172 post-infection, NOSO-502 reduced the urine burden by 2.39 log10 CFU/ml (P ≤ 0.0001), the 173 bladder burden by 1.96 log10 CFU/ml (P = 0.0012), and the kidney burden by 1.36 log10 CFU/ml 174 (P = 0.0123) relative to vehicle (Fig.5) . 175 A neutropenic mouse E. coli ATCC BAA-2469 (NDM-1) intraperitoneal (IP) sepsis infection model 176 was established in male CD-1/ICR mice. Ninety percent of the vehicle-treated mice succumbed 177 to infection prior to the end of the study. All NOSO-502-treated mice (4, 12, and 24 mg/kg) 178 survived up to the end of the study at 24 h (P = 0.0009 relative to vehicle). The vehicle group had 179 a mean and median survival time of 19.8 h and 20.2 h, respectively. One subcutaneous 180 administration of NOSO-502 resulted in statistically significant dose-dependent reductions in 181 blood and IP wash burdens relative to vehicle control animals at all doses. Treatment with 4 mg/kg of NOSO-502 reduced the blood and IP wash burden by 1.48 log10 CFU/ml (P = 0.0081) 183 and 0.68 log10 CFU/ml (P = 0.0145), respectively. Treatment with 12 mg/kg reduced the blood 184 burden by 2.14 log10 CFU/ml (P < 0.0001) and the IP wash burden by 2.07 log10 CFU/ml (P ≤ 185 0.0001) and treatment with 24 mg/kg reduced the blood burden by 2.37 log10 CFU/ml (P ≤ 186 0.0001) and the IP wash burden by 2.74 log10 CFU/ml (P ≤ 0.0001) ( Fig. 6) . 187 A neutropenic mouse K. pneumoniae NCTC 13442 (OXA-48) lung infection model was established 188 in male CD-1/ICR mice. NOSO-502 was administered subcutaneously 2 h, 8 h, 14 h and 20 h post-189 inoculation at set concentrations of 2, 6, and 20 mg/kg (equivalent to 8, 24 and 80 mg/kg/day), 190 whereas tigecycline was administered by the same route at 40 mg/kg (equivalent to 160 191 mg/kg/day). NOSO-502 was also administered once 2 h post-inoculation at 80 mg/kg. Twenty-192 six hours post-challenge, mice were euthanized, and the lungs collected. Administration of 193 NOSO-502 resulted in statistically significant reductions in lung burdens relative to vehicle 194 control animals at all doses. Treatment with 8, 24 and 80 mg/kg/day of NOSO-502 reduced the 195 lung burden by 2.69, 3.99 and 4.07 log10 CFU/gram of lung tissue respectively (P ≤ 0.0001). 196 Treatment with 80 mg/kg once reduced the lung burden by 3.98 log10 CFU/ gram of lung tissue 197 (P ≤ 0.0001) and treatment with 160 mg/kg/day of tigecycline reduced the lung burden by 3.14 198 log10 CFU/ gram of lung tissue (P ≤ 0.0001) ( Fig. 7) .
199

DISCUSSION
200
The urgent need to discover new antibiotics active against Gram-negative bacteria with a novel 201 mechanism of action to counter the threat of drug-resistant infection is widely recognized.
202
NOSO-502 is the first preclinical candidate of a novel antibiotic class, the Odilorhabdins (ODLs). 203 ODLs are cationic peptides that inhibit bacterial translation by a novel mechanism of action. 204 ODLs bind to the small subunit of bacterial ribosomes at a site not exploited by any known 205 ribosome-targeting antibiotic. When bound to the ribosome, ODLs make contacts with both the 206 rRNA and tRNA and kill bacteria by interfering with the decoding of genetic information and 207 inhibiting ribosome progression along the mRNA in a context-specific manner (3). 208 NOSO-502 is active against Enterobacteriaceae, including CRE belonging to all classes of the 209 Ambler classification and resistant to gentamicin, polymyxin B, or tigecycline. This is crucial, 210 because these antibiotics, classically used for the treatment of such infections, are associated 211 with high levels of resistance ranging from 9.7 to 51.3% (mean 22.6%) for colistin, 5.6 to 85.4% 212 (mean 43.5%) for gentamicin, and 0 to 33% (mean 15.2%) for tigecycline (8, 9, 10, 11, 12, 13 Cardiotoxicity issues are associated with many antibiotics, including macrolides, ketolides, and 252 fluoroquinolones. These classes have been associated with prolongation of cardiac 253 repolarization. All these agents produce a blockage of the hERG channel-dependent potassium 254 current in myocyte membranes, resulting in a prolonged QTc interval which may give rise to 255 ventricular fibrillation or tachycardia (35). Nav 1.5 is another channel involved in cardiotoxicity 256 issues. Its activation induces depolarization of the cell membrane. Failure of the Nav 1.5 sodium 257 channel to adequately conduct the electrical current across the cell membrane can result in a 258 potentially fatal disorder. NOSO-502 did not show any effects on hERG or Nav 1.5 channels at 259 high concentrations. 260 Here, we confirmed that NOSO-502, like many other therapeutic peptides, is safe and highly 261 selective. NOSO-502 interacts strongly with a specific site on the 30S subunit of bacterial 262 ribosomes but has no significant activity against any of the 55 cell surface receptors, 263 transporters, or ion channels tested. There is increasing interest in peptides in pharmaceutical is their predisposition to enzymatic degradation. Thus, most do not circulate in blood for more 267 than a few minutes, preventing their usefulness as therapeutic agents. On the contrary, NOSO-268 502 showed good stability in plasma, microsomes, and hepatocytes, probably due to the 269 presence in its structure of three non-standard amino-acid residues: -diamino--hydroxy Time-dependent killing. Time-kill assays were performed by the broth macrodilution method, 291 according to the CLSI guidelines M26-A (39). 292 For preparing the inoculum, between 5 and 30 colonies of a single morphological type from a 293 16-to 24-h Mueller-Hinton agar plate (MHA) were picked and used to inoculate a tube 294 containing 5 ml prewarmed cation-adjusted Mueller-Hinton broth (CA-MHB). The bacterial 295 suspension was incubated at 35°C until it was visibly turbid. The turbidity of the actively growing 296 broth culture was adjusted with CA-MHB to obtain a calculated OD600 between 0.11 and 0.15. 297 Shaken flasks (250 ml) containing 50 ml CA-MHB, with the appropriate NOSO-502 298 concentrations, were inoculated with 0.5 ml exponentially grown bacteria suspension (5 × 10 7 299 cells/ml) to yield a final concentration of approximately 5 × 10 5 cells/ml. Two multiples of the 300 MICs (four and eight) were used to detect differences in killing. Flasks were incubated at 35°C, 301 with shaking at 150 rpm, and aliquots removed at 0, 1, 2, 3, 4, 6, and 24 h for the determination 302 of viable counts. Serial dilutions were prepared in a sterile 0.9% sodium chloride solution and 303 plated on MHA plates. The plates were incubated at 35°C for 24 h, and the number of colonies UK) were allowed to acclimatize for seven days. Following acclimatization, drinking water was 532 replaced by water containing 5% glucose from five days pre-infection. Previously prepared 533 frozen stocks of E. coli UTI89 were diluted to 1 x 10 10 CFU/ml immediately prior to infection. ethical severity endpoint (whichever came first). Mice were anaesthetized using 2.5% 575 isofluorane/97.5% oxygen followed by a pentobarbitone overdose. When mice were deeply 576 unconscious, blood was collected from all animals under terminal cardiac puncture into EDTA 577 blood tubes. In addition, an intraperitoneal wash with sterile PBS (2 ml IP injected, 1 ml removed 578 for culture) was collected. Five mice were also euthanized by pentobarbitone overdose to 579 provide a 1-h pretreatment control group. Blood and IP wash samples were quantitatively 580 cultured onto CLED agar plates and incubated at 37°C for 24 h before colonies were counted. 581 The data from the culture burdens were analyzed using appropriate non-parametric statistical 582 models (Kruskal-Wallis using Conover-Inman to make all pairwise comparisons between groups) 583 with StatsDirect software v. 2.7.8. and compared to pretreatment and vehicle controls. 
